Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
Amphastar Pharmaceuticals (AMPH) Stock Price & Analysis
339 Followers
AMPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$36.56 - $67.66
Previous Close$39.61
Volume48.68K
Average Volume (3M)361.23K
Market Cap
$1.97B
Enterprise Value$2.30B
Total Cash (Recent Filing)$256.81M
Total Debt (Recent Filing)$623.64M
Price to Earnings (P/E)13.7
Beta0.49
Next Earnings
Aug 05, 2024EPS Estimate
$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.90
Shares Outstanding48,901,965
10 Day Avg. Volume326,278
30 Day Avg. Volume361,229
Standard Deviation0.12
R-Squared0.14
Alpha0.00939
Financial Highlights & Ratios
Price to Book (P/B)75.71
Price to Sales (P/S)3.07
Price to Cash Flow (P/CF)20.70
P/FCF Ratio21.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.03
Enterprise Value/Gross Profit6.56
Enterprise Value/Ebitda9.30
Forecast
1Y Price Target
$70.50Price Target Upside74.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Amphastar Pharmaceuticals News
PremiumCompany Announcements
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
Bulls Say, Bears Say
Bulls Say
Market PositioningAMPH is well positioned to gain share with its albuterol inhaler.
Product ApprovalAMPH announced it received approval for its albuterol inhaler, which is bioequivalent to Teva's ProAir HFA.
Product LaunchesManagement expects 4 - 5 new product launches.
Bears Say
Market CompetitionThe market for albuterol sulfate inhalation solution is highly competitive with multiple branded products, authorized generics, and generic products.
Pricing PressuresHigher fees to wholesalers are creating headwinds, leading to low single-digit pricing declines.
Product DistributionThe transition of Baqsimi distribution from Lilly is proceeding slower than expected, impacting revenues and operating expenses.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AMPH FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was $36.56 and its highest was $67.66 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Currently, no data Available
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on May 08, 2024. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.773 by $0.267.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is $0.77.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 48,901,966 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of $1.04 in its last earnings report, beating expectations of $0.773. Following the earnings report the stock price went up 0.521%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Among the largest hedge funds holding Amphastar Pharmaceuticals’s share is Hussman Strategic Advisors Inc. It holds Amphastar Pharmaceuticals’s shares valued at 3M.
---
Amphastar Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.50 (74.85% Upside)
$70.50 (74.85% Upside)
Blogger Sentiment
Bullish
AMPH Sentiment 88%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 89.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $124.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.45%
12-Months-Change
Fundamentals
Return on Equity
25.34%
Trailing 12-Months
Asset Growth
103.49%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
AMPH Company Deck
---
AMPH Earnings Call
Q1 2024
0:00 / 0:00
---
AMPH Stock 12 Month Forecast
Average Price Target
$70.50
▲(74.85% Upside)
Technical Analysis
Best Analysts Covering AMPH
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+25.98%
reiterated a buy rating 2 months ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +25.98% per trade.
---